189 related articles for article (PubMed ID: 20709547)
1. The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.
Aspiotis R; Deschênes D; Dubé D; Girard Y; Huang Z; Laliberté F; Liu S; Papp R; Nicholson DW; Young RN
Bioorg Med Chem Lett; 2010 Sep; 20(18):5502-5. PubMed ID: 20709547
[TBL] [Abstract][Full Text] [Related]
2. Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.
Lacombe P; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Gallant M; Girard Y; Huang Z; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini JA; Masson P; Nicholson DW; Nicoll-Griffith DA; Salem M; Styhler A; Young RN
Bioorg Med Chem Lett; 2009 Sep; 19(17):5266-9. PubMed ID: 19640717
[TBL] [Abstract][Full Text] [Related]
3. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
Woodrow MD; Ballantine SP; Barker MD; Clarke BJ; Dawson J; Dean TW; Delves CJ; Evans B; Gough SL; Guntrip SB; Holman S; Holmes DS; Kranz M; Lindvaal MK; Lucas FS; Neu M; Ranshaw LE; Solanke YE; Somers DO; Ward P; Wiseman JO
Bioorg Med Chem Lett; 2009 Sep; 19(17):5261-5. PubMed ID: 19656678
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y
Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
Gallant M; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Huang Z; Lacombe P; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini J; Masson P; Mastracchio A; Nicholson D; Nicoll-Griffith DA; Perrier H; Salem M; Styhler A; Young RN; Girard Y
Bioorg Med Chem Lett; 2008 Feb; 18(4):1407-12. PubMed ID: 18207397
[TBL] [Abstract][Full Text] [Related]
6. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.
Lunniss CJ; Cooper AW; Eldred CD; Kranz M; Lindvall M; Lucas FS; Neu M; Preston AG; Ranshaw LE; Redgrave AJ; Ed Robinson J; Shipley TJ; Solanke YE; Somers DO; Wiseman JO
Bioorg Med Chem Lett; 2009 Mar; 19(5):1380-5. PubMed ID: 19195882
[TBL] [Abstract][Full Text] [Related]
7. Identification of pyridazino[4,5-b]indolizines as selective PDE4B inhibitors.
Donnell AF; Dollings PJ; Butera JA; Dietrich AJ; Lipinski KK; Ghavami A; Hirst WD
Bioorg Med Chem Lett; 2010 Apr; 20(7):2163-7. PubMed ID: 20202838
[TBL] [Abstract][Full Text] [Related]
8. Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.
Zhou ZZ; Ge BC; Chen YF; Shi XD; Yang XM; Xu JP
Bioorg Med Chem; 2015 Nov; 23(22):7332-9. PubMed ID: 26526739
[TBL] [Abstract][Full Text] [Related]
9. Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors.
Lacombe P; Deschênes D; Dubé D; Dubé L; Gallant M; Macdonald D; Mastracchio A; Perrier H; Charleson S; Huang Z; Laliberté F; Liu S; Mancini JA; Masson P; Salem M; Styhler A; Girard Y
Bioorg Med Chem Lett; 2006 May; 16(10):2608-12. PubMed ID: 16516471
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors.
Nikpour M; Sadeghian H; Saberi MR; Nick RS; Seyedi SM; Hosseini A; Parsaee H; Bozorg AT
Bioorg Med Chem; 2010 Jan; 18(2):855-62. PubMed ID: 20005117
[TBL] [Abstract][Full Text] [Related]
11. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
[TBL] [Abstract][Full Text] [Related]
12. Pyrazolopyridines as potent PDE4B inhibitors: 5-heterocycle SAR.
Mitchell CJ; Ballantine SP; Coe DM; Cook CM; Delves CJ; Dowle MD; Edlin CD; Hamblin JN; Holman S; Johnson MR; Jones PS; Keeling SE; Kranz M; Lindvall M; Lucas FS; Neu M; Solanke YE; Somers DO; Trivedi NA; Wiseman JO
Bioorg Med Chem Lett; 2010 Oct; 20(19):5803-6. PubMed ID: 20732811
[TBL] [Abstract][Full Text] [Related]
13. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.
Owen DR; Walker JK; Jon Jacobsen E; Freskos JN; Hughes RO; Brown DL; Bell AS; Brown DG; Phillips C; Mischke BV; Molyneaux JM; Fobian YM; Heasley SE; Moon JB; Stallings WC; Joseph Rogier D; Fox DN; Palmer MJ; Ringer T; Rodriquez-Lens M; Cubbage JW; Blevis-Bal RM; Benson AG; Acker BA; Maddux TM; Tollefson MB; Bond BR; Macinnes A; Yu Y
Bioorg Med Chem Lett; 2009 Aug; 19(15):4088-91. PubMed ID: 19540112
[TBL] [Abstract][Full Text] [Related]
14. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.
Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Linget JM; Kirilovsky J; Hyafil F; Labaudinière R
J Med Chem; 2003 Oct; 46(21):4533-42. PubMed ID: 14521415
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors.
Kuang R; Shue HJ; Blythin DJ; Shih NY; Gu D; Chen X; Schwerdt J; Lin L; Ting PC; Zhu X; Aslanian R; Piwinski JJ; Xiao L; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Minnicozzi M; Billah M; Wang P
Bioorg Med Chem Lett; 2007 Sep; 17(18):5150-4. PubMed ID: 17683932
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.
Andrés JI; Buijnsters P; De Angelis M; Langlois X; Rombouts F; Trabanco AA; Vanhoof G
Bioorg Med Chem Lett; 2013 Feb; 23(3):785-90. PubMed ID: 23260348
[TBL] [Abstract][Full Text] [Related]
17. 8-Methoxyquinolines as PDE4 inhibitors.
Billah M; Buckley GM; Cooper N; Dyke HJ; Egan R; Ganguly A; Gowers L; Haughan AF; Kendall HJ; Lowe C; Minnicozzi M; Montana JG; Oxford J; Peake JC; Picken CL; Piwinski JJ; Naylor R; Sabin V; Shih NY; Warneck JB
Bioorg Med Chem Lett; 2002 Jun; 12(12):1617-9. PubMed ID: 12039575
[TBL] [Abstract][Full Text] [Related]
18. Discovery of selective PDE4B inhibitors.
Naganuma K; Omura A; Maekawara N; Saitoh M; Ohkawa N; Kubota T; Nagumo H; Kodama T; Takemura M; Ohtsuka Y; Nakamura J; Tsujita R; Kawasaki K; Yokoi H; Kawanishi M
Bioorg Med Chem Lett; 2009 Jun; 19(12):3174-6. PubMed ID: 19447034
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of N-acyl pyrroloquinolone PDE-5 inhibitors.
Lanter JC; Sui Z; Macielag MJ; Fiordeliso JJ; Jiang W; Qiu Y; Bhattacharjee S; Kraft P; John TM; Haynes-Johnson D; Craig E; Clancy J
J Med Chem; 2004 Jan; 47(3):656-62. PubMed ID: 14736245
[TBL] [Abstract][Full Text] [Related]
20. Discovery of oxazole-based PDE4 inhibitors with picomolar potency.
Kuang R; Shue HJ; Xiao L; Blythin DJ; Shih NY; Chen X; Gu D; Schwerdt J; Lin L; Ting PC; Cao J; Aslanian R; Piwinski JJ; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Billah M; Wang P
Bioorg Med Chem Lett; 2012 Apr; 22(7):2594-7. PubMed ID: 22401864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]